Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital
Stephen Capone, Shogik Abramyan, Brent Ross, Joshua Rosenberg, John Zeibeq, Viswanath Vasudevan, Reza Samad, Louis Gerolemou, Evgeny Pinelis, James Gasperino, Jose Orsini
Cureus, doi:10.7759/cureus.9809
Background The novel coronavirus disease 2019 (COVID-19) pandemic continues to spread across the country with over 3 million cases and 150,000 deaths in the United States as of July 2020. Outcomes have been poor, with reported admission rates to the intensive care team of 5% in China and mortality among critically ill patients of 50% in Seattle. Here we explore the disease characteristics in a Brooklyn safety-net hospital affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
Methods A retrospective chart review of COVID-19 positive patients at The Brooklyn Hospital Center who were treated by the intensive care team prior to April 20, 2020. Data was extracted from the electronic health record, analyzed and correlated for outcome.
Results Impact of various clinical treatments was assessed, showing no change in median overall survival (OS) of both hydroxychloroquine with azithromycin or vitamin C with zinc. Supplemental therapies were used in selected patients, and some were shown to increase median OS and patients requiring vasopressor support or invasive mechanical ventilation showed decreased OS. There was no statistically significant difference in overall survival based on ethnicity, healthcare status, or individual medical comorbidities, although a negative trend exists for diabetes. Despite this, there is a trend towards increasingly poor prognosis based on the number of comorbidities and Class 3 obesity.
Conclusions Despite the fact that we show no significant differences in mortality based on ethnicity, insurance status, or individual medical comorbidities, we show a high overall mortality. There is also a trend towards increased overall mortality in Class 3 obesity, which should be further investigated. We suggest that these findings may be attributed to both socioeconomic factors and an increased incidence of total medical comorbidities in our patient population.
Additional Information Disclosures Human subjects: Consent was obtained by all participants in this study. The Brooklyn Hospital Center issued approval 1595421. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might
References
Bhatraju, Ghassemieh, Nichols, COVID-19 in critically ill patients in the Seattle region -case series, N Engl J Med,
doi:10.1056/nejmoa2004500Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis,
doi:10.1016/0021-9681(87)90171-8Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)31189-2Gattinoni, Coppola, Cressoni, Busana, Rossi et al., COVID-19 does not lead to a "typical" acute respiratory distress syndrome, Am J Respir Crit Care Med,
doi:10.1164/rccm.202003-0817LEGautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Grasselli, Pesenti, Cecconi, Critical care utilization for the COVID-19 outbreak in Lombardy, Italy, JAMA,
doi:10.1001/jama.2020.4031Mahévas, Tran, Roumier, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen : results of a study using routinely collected data to emulate a target trial, medRxiv,
doi:10.1101/2020.04.10.20060699Oxley, Mocco, Majidi, Large-vessel stroke as a presenting feature of COVID-19 in the young, N Engl J Med,
doi:10.1056/NEJMc2009787Pan, Chen, Lu, Lung recruitability in SARS-CoV-2 associated acute respiratory distress syndrome: a single-center, observational study, Am J Respir Crit Care Med,
doi:10.1164/rccm.202003-0527LEPetrilli, Jones, Yang, Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New,
doi:10.1101/2020.04.08.20057794Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA,
doi:10.1001/jama.2020.6775Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (Covid-19) outbreak in China, JAMA,
doi:10.1001/jama.2020.2648Zhang, Xiao, Zhang, Coagulopathy and antiphospholipid antibodies in patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMc2007575
